a strong trendP = 0.051
In the ON-TIME 2 Trial, the patients who received high-dose bolus Tirofiban (25 mcg/kg) before primary PCI exhibited a strong trend toward a decrease in mortality (2.2 % vs. 4.1 %, P = 0.051), which was maintained during one year's follow-up (3.7 % vs. 5.8 %, p value = 0.08) ( 30 ).